Indian Pharma Lobby Says Delhi High Court Exceeded Its Authority In Restraining Hetero Dasatinib Application Due To BMS Petition
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The recent decision of the Delhi High Court restraining the Drug Controller General of India from approving Hetero's dasatinib has drawn flak from the Indian Pharmaceutical Alliance - a group that represents the most influential Indian drug companies. The court had barred India's drug regulatory agency from approving Hetero's application on a petition filed by Bristol-Myers Squibb, maker of the brand drug Sprycel
You may also be interested in...
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs
On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations
MUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized